Liang; Meina
Patent Applications and Registrations
Patent applications and USPTO patent grants for Liang; Meina.The latest application filed is for "ccl20 as a predictor of clinical response to il23-antagonists".
Company Profile
7.21.24
- Liang; Meina - Gaithersburg MD
- Liang; Meina - Fremont CA
- Liang; Meina - Santa Clara CA
- Liang; Meina - Danville CA
Patent Activity
| Patent | Date |
|---|---|
| Ccl20 As A Predictor Of Clinical Response To Il23-antagonists App 20220144935 - Georgantas, III; Robert W. ; et al. | 2022-05-12 |
| CCL20 as a predictor of clinical response to IL23-antagonists Grant 11,220,541 - Georgantas, III , et al. January 11, 2 | 2022-01-11 |
| Anti-b7-h1 Antibodies For Treating Tumors App 20210171639 - NARWAL; RAJESH ; et al. | 2021-06-10 |
| Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers Grant 11,016,099 - Georgantas, III , et al. May 25, 2 | 2021-05-25 |
| Anti-B7-H1 antibodies for treating tumors Grant 10,829,557 - Narwal , et al. November 10, 2 | 2020-11-10 |
| Anti-pad4 Autoantibodies As Clinical Response Biomarkers For The Treatment Of Rheumatoid Arthritis App 20200317793 - MOATE; Rachel Patricia ; et al. | 2020-10-08 |
| Methods of using antibodies to determine periostin levels in a sample Grant 10,775,388 - Chowdhury , et al. Sept | 2020-09-15 |
| Ccl20 As A Predictor Of Clinical Response To Il23-antagonists App 20200262907 - Georgantas, III; Robert W. ; et al. | 2020-08-20 |
| Anti-b7-h1 Antibodies For Treating Tumors App 20190338033 - Narwal; Rajesh ; et al. | 2019-11-07 |
| Anti-B7-H1 antibodies for treating tumors Grant 10,336,823 - Narwal , et al. | 2019-07-02 |
| Prediction Of Clinical Response To Il23-antagonists Using Il23 Pathway Biomarkers App 20180252728 - Georgantas, III; Robert W. ; et al. | 2018-09-06 |
| Novel Assay To Detect Human Periostin App 20180196065 - Chowdhury; Partha ; et al. | 2018-07-12 |
| Novel Assay To Detect Human Periostin App 20180179272 - Chowdhury; Partha ; et al. | 2018-06-28 |
| Monoclonal antibodies which bind human periostin Grant 9,862,762 - Chowdhury , et al. January 9, 2 | 2018-01-09 |
| Dipeptidyl Peptidase-4 (dpp4/cd26) As A Peripheral Biomarker Of Il-13 Activation In Asthmatic Lung App 20160363591 - Streicher; Katie ; et al. | 2016-12-15 |
| Antibodies Directed To GPNMB And Uses Thereof App 20160311919 - Xiao; Feng ; et al. | 2016-10-27 |
| Novel Assay To Detect Human Periostin App 20160311894 - Chowdhury; Partha ; et al. | 2016-10-27 |
| Anti-B7-H1 Antibodies for Treating Tumors App 20160222120 - Narwal; Rajesh ; et al. | 2016-08-04 |
| Nucleic acids encoding antibodies to CCR2 Grant 9,238,691 - Gladue , et al. January 19, 2 | 2016-01-19 |
| Antibodies Directed to GPNMB and Uses Thereof App 20150044212 - Xiao; Feng ; et al. | 2015-02-12 |
| Antibodies directed to GPNMB and uses thereof Grant 8,846,873 - Xiao , et al. September 30, 2 | 2014-09-30 |
| Antibodies to CCR2 Grant 8,710,191 - Gladue , et al. April 29, 2 | 2014-04-29 |
| Antibodies Directed To GPNMB And Uses Thereof App 20130022597 - Xiao; Feng ; et al. | 2013-01-24 |
| Antibodies directed to tumor necrosis factor and uses thereof Grant 8,101,178 - Babcook , et al. January 24, 2 | 2012-01-24 |
| Antibodies To Ccr2 App 20110274696 - Gladue; Ronald P. ; et al. | 2011-11-10 |
| Antibodies Directed To Tumor Necrosis Factor And Uses Thereof App 20080187531 - Babcook; John S. ; et al. | 2008-08-07 |
| Antibodies directed to tumor necrosis factor Grant 7,285,269 - Babcook , et al. October 23, 2 | 2007-10-23 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 7,268,140 - Bauman , et al. September 11, 2 | 2007-09-11 |
| Substituted quinoline CCR5 receptor antagonists Grant 7,220,856 - Dunning , et al. May 22, 2 | 2007-05-22 |
| Piperazine derivatives and their use as anti-inflammatory agents App 20060135487 - Bauman; John G. ; et al. | 2006-06-22 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,977,258 - Bauman , et al. December 20, 2 | 2005-12-20 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,972,290 - Bauman , et al. December 6, 2 | 2005-12-06 |
| Antibodies directed to phospholipase A2 and uses thereof App 20050058649 - Landes, Gregory M. ; et al. | 2005-03-17 |
| Antibodies directed to tumor necrosis factor and uses thereof App 20050049402 - Babcook, John S. ; et al. | 2005-03-03 |
| Substituted quinoline CCR5 receptor antagonists App 20040072818 - Dunning, Laura ; et al. | 2004-04-15 |
| Piperazine derivatives and their use as anti-inflammatory agents App 20030158205 - Bauman, John G. ; et al. | 2003-08-21 |
| Piperazine derivatives and their use as anti-inflammatory agents App 20030139425 - Bauman, John G. ; et al. | 2003-07-24 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,555,537 - Bauman , et al. April 29, 2 | 2003-04-29 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,541,476 - Bauman , et al. April 1, 2 | 2003-04-01 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,534,509 - Bauman , et al. March 18, 2 | 2003-03-18 |
| Piperazine derivatives and their use as anti-inflammatory agents App 20020177598 - Bauman, John G. ; et al. | 2002-11-28 |
| Piperazine derivatives and their use as anti-inflammatory agents Grant 6,207,665 - Bauman , et al. March 27, 2 | 2001-03-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 